1-[三(1-甲基乙基)甲硅烷基]-1H-吡咯并[2,3-b]-5-氨基吡啶 | 651744-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 1-[三(1-甲基乙基)甲硅烷基]-1H-吡咯并[2,3-b]-5-氨基吡啶
• 英文名称: 1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridin-5-amine
• 英文别名: N-triisopropylsilyl 5-amino-7-azaindole；1H-Pyrrolo[2,3-B]pyridin-5-amine, 1-[tris(1-methylethyl)silyl]-；1-tri(propan-2-yl)silylpyrrolo[2,3-b]pyridin-5-amine
• CAS: 651744-47-7
• 化学式: C₁₆H₂₇N₃Si
• 分子量: 289.496
• InChiKey: UIZPXXJMWKJZRD-UHFFFAOYSA-N

物化性质

• 沸点：
  344.5±35.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.64
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[三(1-甲基乙基)甲硅烷基]-1H-吡咯并[2,3-b]-5-氨基吡啶 、 4-氯-5-甲基吡咯[2,1-F][1,2,4]三嗪-6-羧酸甲酯 在 N,N-二异丙基乙胺 作用下， 生成
  参考文献：
  名称：

  Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor

  摘要：

  We report herein a series of substituted N-(1H-pyrrolo[2,3-b] pyridin-5-yl) pyrrolo[2,1-f][1,2,4] triazin-4-amines as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. Through structure-activity relationship studies, biochemical potency, pharmacokinetics, and kinase selectivity were optimized to afford BMS-645737 (13), a compound with good preclinical in vivo activity against human tumor xenograft models. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.057
• 作为产物：
  描述：

  4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-5-ylamine 在 锌 乙酸乙酯 、 crude product 、 silica gel 、 hexanes 作用下， 以 乙酸乙酯 、 溶剂黄146 为溶剂， 反应 4.0h， 以to afford 1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-5-ylamine (6.38 g)的产率得到1-[三(1-甲基乙基)甲硅烷基]-1H-吡咯并[2,3-b]-5-氨基吡啶
  参考文献：
  名称：

  Azaindole kinase inhibitors

  摘要：

  本发明提供了I式化合物及其药学上可接受的盐。I式化合物抑制生长因子受体的酪氨酸激酶活性，如VEGFR-2和FGFR-1，因此使它们有用作抗癌剂。I式化合物也可用于治疗通过生长因子受体操作的信号转导途径引起的其他疾病。

  公开号：

  US06969717B2

文献信息

• [EN] AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS<br/>[FR] AMINO-BENZAZOLES UTILISES COMME INHIBITEURS DU RECEPTEUR P2Y1
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005070920A1

  公开（公告）日：2005-08-04

  The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.

  本发明提供了新颖的氨基苯并唑及其类似物，这些化合物是人类P2Y1受体的选择性抑制剂。该发明还提供了相应的各种药物组合物以及治疗对P2Y1受体活性调节敏感的疾病的方法。
• AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS
  申请人：Herpin Timothy F.

  公开号：US20080275090A1

  公开（公告）日：2008-11-06

  The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型的氨基苯并咪唑及其类似物，它们是选择性抑制人类P2Y1受体的抑制剂。本发明还提供了各种药物组合物和方法，用于治疗对P2Y1受体活性调节敏感的疾病。
• Amino-benzazoles as P2Y1 receptor inhibitors with pyridine ring and heterocyclic components
  申请人：Bristol-Myers Squibb Company

  公开号：US08053450B2

  公开（公告）日：2011-11-08

  The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.

  本发明提供了新型的氨基苯并咪唑及其类似物，它们是人类P2Y1受体的选择性抑制剂。该发明还提供了各种药物组合物和治疗对P2Y1受体活性调节敏感的疾病的方法。
• Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor
  作者：Réjean Ruel、Carl Thibeault、Alexandre L’Heureux、Alain Martel、Zhen-Wei Cai、Donna Wei、Ligang Qian、Joel C. Barrish、Arvind Mathur、Celia D’Arienzo、John T. Hunt、Amrita Kamath、Punit Marathe、Yueping Zhang、George Derbin、Barri Wautlet、Steven Mortillo、Robert Jeyaseelan、Benjamin Henley、Ravindra Tejwani、Rajeev S. Bhide、George L. Trainor、Joseph Fargnoli、Louis J. Lombardo

  DOI：10.1016/j.bmcl.2008.03.057

  日期：2008.5

  We report herein a series of substituted N-(1H-pyrrolo[2,3-b] pyridin-5-yl) pyrrolo[2,1-f][1,2,4] triazin-4-amines as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. Through structure-activity relationship studies, biochemical potency, pharmacokinetics, and kinase selectivity were optimized to afford BMS-645737 (13), a compound with good preclinical in vivo activity against human tumor xenograft models. (C) 2008 Elsevier Ltd. All rights reserved.
• Azaindole kinase inhibitors
  申请人：Bhide S. Rajeev

  公开号：US20060058304A1

  公开（公告）日：2006-03-16

  The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了I式化合物及其药学上可接受的盐。I式化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，因此可用作抗癌剂。I式化合物还可用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。